Search academic texts

Information × Registration Number 0214U006904, 0111U001372 , R & D reports Title Features of a current, diagnostics and treatment of an accompanying pathology in endocrine diseases popup.stage_title Head Pertseva Tatyana Oleksiivna, Registration Date 06-03-2014 Organization Dniepropetrovsk State Medical Academy popup.description2 The evaluation system of predicting the effectiveness of treatment of arterial hypertension, obesity. Improvement of forecasting accuracy of the further course of obesity, metabolic syndrome condition of kidneys, and other related conditions, and establishing the main and additional criteria for risk of complications in patients with endocrine disorders. Improved diagnosis of metabolic syndrome, insulin resistance, a condition of kidneys, blood rheological properties. Optimized approaches to diagnostics and treatment of patients with arterial hypertension with increased body mass index, by developing ways of correction of arterial blood pressure sensitivity to insulin, and changes in the lipid and carbohydrate metabolism. Extended criteria of appointment of glucose-lowering therapy in patients with first diagnosed with diabetes type 2 diabetes with obesity (BMI 30 kg/m2) through the identification and combination of carbohydrate exchange and markers of insulin resistance in the light of lipid; study of the dynamics of these indicators under the influence of differentiated schemes pathogenetically caused by glucose-lowering therapy. The essence of the results: The prevalence of disorders of carbohydrate metabolism, lipid and indicators of insulin resistance (IR) in patients with newly diagnosed type 2 DM obesity ( BMI > 30 kg/m2) through the conduct of clinical and anamnestic and laboratory studies of patients . To assess the impact of pathogenetically caused by differentiated schemes glucose-lowering therapy in patients on anthropometric indicators (BMI, here, HERE/PERSON), as well as the status of carbohydrate metabolism, markers of insulin resistance and lipid spectrum. Develop practical recommendations based on the conducted research; implement the developed recommendations to practical medicine. Define the frequency of occurrence arterial hypertension and associated components of the metabolic syndrome in patients with a body mass index over 30 kg/m2. It is shown that obesity for abdominal type - early factor that is ahead of the manifestations of arterial hypertension and metabolic changes in the groups of patients that need correction insulin resistance status, lipid shifts informed early announcement of lipid lowering therapy for patients with diabetes and hypertension as prevention of progression of cardiovascular disease. For the first time studied the connection between the level of insulin resistance at various mass of the body and features of arterial hypertension, The advantage of the work Developed, tested and implemented as a sector-specific innovations optimized methodology for setting differentiated pathogenetically caused by glucose-lowering therapy in patients with first diagnosed with diabetes type 2 diabetes with obesity (BMI > 30 kg/m2) depending on the combination of carbohydrate metabolism (GBV) , as well as markers of insulin resistance (that's index NOMA-IR), the proposed scheme with individual diagnosis and treatment of patients with cardio-vascular pathology depending on the endocrine status of the patient and the degree of obesity. Results of this work can be used for practical doctors and scientists to optimize treatment of patients. The results of a study of patients with cardiovascular and other disorders put into practice the work of the endocrinology and internal medicine departments. According to the results of research відано 22 print publications, including 1 tutorial. The report is printed on 127 pages and consists of: introduction, the abstract review of the literature, methods of research, 3 chapters of their own observations, opinions, findings, recommendations and the list of references. Key words : obesity, diabetes mellitus, arterial hypertension, renal dysfunction , dislipidemia, insulin resistance, gemostaz. Product Description popup.authors Маляр Катерина Юріївна Марцинік Евген Миколайович Перцева Тетяна Олексіївна Рокутова Марія Камільївна Турлюн Тамара Сергіївна popup.nrat_date 2020-04-02 Close